Compare Autodesk Inc (ADSK) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autodesk Inc vs Incyte Corporation — how do they compare? Autodesk Inc trades at $248.22 (market cap $53.12B), while Incyte Corporation trades at $120.76 (market cap $24.54B). The key difference: Autodesk Inc is far larger — about 2.2× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Autodesk Inc nearer its low. Which is the better fit depends on your goals.
| ADSK | INCY | |
|---|---|---|
Market Cap | $53.12B | $24.54B |
Sector | Technology | Health |
52-Week High | $326.79 | $129.93 |
52-Week Low | $187.72 | $81.61 |
Enterprise Value | $52.92B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $247.39, down 3.39% in the latest session, but maintains strong fundamentals with consistent earnings beats and robust revenue growth. The stock shows a bullish technical trend with moving averages supporting upside momentum, while RSI levels indicate potential overbought conditions. Recent financial performance demonstrates expanding profit margins and healthy cash flow generation, supported by the company's dominant position in design software markets.
The outlook remains positive with analyst consensus favoring continued growth, though elevated valuation multiples and competitive pressures present risks. Upside potential exists toward the $302.23 consensus price target, supported by strong institutional backing and strategic AI investments. Key risks include market volatility and execution challenges in maintaining premium valuation levels.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
